Rationale: Mammalian heart has minimal regenerative capacity. In response to mechanical or pathological stress, the heart undergoes cardiac remodeling. Pressure and volume overload in the heart cause increased size (hypertrophic growth) of cardiomyocytes. Whereas the regulatory pathways that activate cardiac hypertrophy have been well-established, the molecular events that inhibit or repress cardiac hypertrophy are less known.
C omplex genetic pathways intimately regulate heart development and function. 1 Much of our current understanding of how cardiac gene expression is controlled is at the level of transcriptional regulation, in which multiple tissuespecific transcription factors have been implicated in the control of gene expression during cardiomyocyte differentiation. 2 Those include Nkx2.5, a homeobox protein, [3] [4] [5] MEF2C, a member of the myocyte enhance factor-2 (MEF2) family of MADS-box transcription factors, 6 -11 and GATA4, a GATA family zinc finger protein. 12, 13 Some of the wellcharacterized cardiac genes regulated by these cardiac transcription factors include cardiac-specific atrial natriuretic factor and cardiac ␣-actin. 13, 14 Two distinct sources of cardiac precursor cells from the "primary" and "secondary heart fields" participate in heart formation. [15] [16] [17] Whereas the primary heart field is essential for the formation of the initial heart tube, additional cardiac precursor cells recruited from the secondary heart field contribute to the future right ventricle and outflow tract. 18, 19 Loss-of-function studies have defined genes whose activity is required in secondary heart field progenitors for morphogenesis of outflow tract and right ventricle. 18, 20 Among the genes with key function in secondary heart field is Isl1, a LIM/ homeodomain transcription factor. [21] [22] [23] [24] One of the major responses of the heart to biomechanical stress and pathological stimuli is to undergo cardiac hypertrophy, an increase in the thickness of the cardiac ventricular wall. At a cellular level, cardiac hypertrophy is defined as an increase of cardiomyocyte size. 25, 26 Initially, cardiac hypertrophy is an adaptive response that maintains cardiac output in the face of increased workload. However, chronic activation of hypertrophic pathways is associated with adverse consequences that may lead to heart failure and sudden death. 27 Cardiac hypertrophy occurs in response to a variety of mechanical, hemodynamic, hormonal, and pathological stimuli. 28 -30 Numerous studies have demonstrated that many signaling pathways and transcriptional networks that normally regulate different aspects of cell proliferation, differentiation, and survival are also involved in the induction of cardiac hypertrophy. 1, 29, 31 Hypertrophic growth involves control of cardiomyocyte gene expression at multiple molecular levels. Key regulators of gene expression in cardiac myocytes such as members of the MEF2 and GATA families are involved in the control of gene expression during cardiomyocyte hypertrophy. Epigenetic regulation of gene expression, including histone modification by histone acetyltransferases and histone deacetylases to remodel chromatin, has been proven as another mean of hypertrophic regulation. 32, 33 Cardiac hypertrophy is also accompanied by reactivation of a set of cardiac fetal genes, including those that encode atrial natriuretic factor, B-type natriuretic peptide, and ␤ myosin heavy chain. 26 Reactivation of these fetal genes suggests that molecular pathways that control heart development are redeployed to regulate hypertrophic growth. 34 The pathophysiology of cardiac hypertrophy has been extensively studied for decades and much is known about signaling pathways that activate cardiac hypertrophy. 26, 30 However, relatively less is known about how cardiac hypertrophy is repressed.
We previously identified myocardin as a SAP (SAF-A/B, Acinus, PIAS) domain transcriptional regulator. 35, 36 Myocardin is expressed in both cardiomyocytes and a subset of vascular and visceral smooth muscle cell types. 35, 36 Myocardin does not to bind DNA directly, but rather forms a stable ternary complex with serum response factor bound to DNA. 37, 38 As a transcriptional cofactor of serum response factor, myocardin potently transactivates CArG boxcontaining reporter genes. 36, 39, 40 Genetic studies revealed that myocardin and myocardin-related transcription factors play critical roles in a variety of biological processes, including vascular smooth muscle development, aortic vessel patterning, mammary myoepithelium formation, and others. [41] [42] [43] In this study, we report the identification and characterization of a novel cardiac-specific nuclear protein, cardiac Isl1interacting protein (CIP). CIP interacts with the LIM/homeodomain transcription factor Isl1. We showed that the expression of CIP was repressed in hypertrophic hearts and, most importantly, CIP represses cardiomyocyte hypertrophy.
Methods
An expanded Methods section is provided in the Online Supplement.
Results

Identification of CIP, a Novel Gene From Mouse Hearts
We searched expressed sequence tag databases for novel sequences present in cardiac cDNA libraries. Previously, this approach succeeded in identifying myocardin as a novel cardiac-specific and smooth muscle-specific transcription cofactor for serum response factor. 36 An additional candidate expressed sequence tag sequence recovered in the search (GenBank Accession Number AA919489) contained a short 273 nucleotide tag that was derived from a mouse embryonic day 13 (embryonic day 13.5) heart cDNA library. Using this sequence as a probe to screen a mouse embryonic heart cDNA library, we identified a larger cDNA sequence of 1336 nucleotides encoding a putative protein of 309 amino acids, which we name CIP (cardiac Isl1-interesting protein; Figure  1A ). Genbank Database search indicated that this cDNA clone is similar to RIKEN cDNA clone 2310046A06Rik and is a novel alternative slicing-produced isoform of a recently reported protein called MLIP (muscle-enriched A-type lamininteracting protein). 44 In addition to the putative lamin-A interaction domain in its N-terminus, CIP contains an AThook DNA binding domain in its C-terminus (aa 212-224), suggesting that CIP could function as a DNA-binding transcriptional regulator ( Figure 1A , C; Online Figure I ). Furthermore, the CIP protein contains a putative asparagine glycosylation site (aa 223-226), a poly serine stretch (aa 225-229), and a tyrosine phosphorylation site (aa 254 -260; Figure 1A ). Northern blot analysis using an adult mouse multiple tissue blot demonstrated that the expression of CIP is restricted to the heart. Two major transcripts, Ϸ1.4 K and Ϸ3.4 K nucleotides, respectively, were detected in the heart and likely represent products of alternative splicing ( Figure 1B) . The cDNA sequence we have cloned represents the Ϸ1.4 kb transcript, whereas the sequences of the Ϸ3.4 kb remain to be identified.
The Cip gene contains at least eight exons and spans over 245 kb on mouse chromosome 9. Cip is evolutionary, conserved from fish to human (Online Figure II) . Sequencing of Cip reverse-transcriptase polymerase chain reaction products identified complex alternative splicing ( Figure 1C ). The functional significance of those isoforms is currently not clear. Next, we examined the subcellular location of the CIP protein. We transiently overexpressed Flag-CIP fusion proteins in COS7 and Hela cells. Immunochemistry assays revealed that the Flag-CIP fusion proteins are primarily located in the nuclei of transfected cells. We also observed a weaker distribution of the Flag-CIP proteins in the cytoplasm ( Figure 1D ).
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CIP Expression Is Restricted to Cardiomyocytes of Developing Hearts
To define the expression pattern of Cip during development, in situ hybridization was performed using an antisense probe to the 3Ј untranslated region of the mouse Cip transcript. Whole-mount in situ hybridization first demonstrated that CIP expression is restricted to the heart of embryonic day 9.5 mouse embryos, with highest expression level detected in the ventricle (Figure 2A ). In situ hybridization on tissue sections of staged mouse embryos revealed that Cip expression was first detected in the heart of embryonic day 8.5 mouse embryos ( Figure 2B ). Cip continued to be restricted to the heart from embryonic day 9.5 to embryonic day 15.5 ( Figure  2C , D, E, F, G). An apparently positive signal was also detected in the truck of embryonic day 9.5 embryo, which might represent transient expression of CIP in presomitic mesoderm ( Figure 2C ). From embryonic day 11.5 to embryonic day 15.5, Cip expression appeared to be higher in the ventricles of embryonic hearts (Figure 2E , F, G). Myocardial Cip expression continued in the adult heart ( Figure 2H ).
Because the heart consists of cardiomyocyte, cardiac fibroblast, smooth muscle cell, endothelial cell, and epicardial cell, we performed additional experiments to determine exactly in which cell type/lineage the CIP is expressed. First, we utilized a genetic approach in which the Rosa-mT-mG reporter line was used to trace the expression of CIP in different cell types. The Rosa-mT-mG mice possess loxP sites on both sides of a membrane-targeted tdTomato (mT) cassette and express strong red fluorescence in all tissues and cell types ( Figure 3A, B) . The presence of Cre will lead to the deletion of the mT cassette and the activation of the downstream membrane-targeted enhanced green fluorescent protein (EGFP) (mG) cassette ( Figure 3A ). The membrane-targeted EGFP can be utilized as a marker for fluorescence-activated cell sorting ( Figure 3D ). To label and sort out the cardiomyocytes, the Rosa-mT-mG mice were bred with the cTNT-Cre mice, in which the Cre recombinase is driven by the cardiomyocyte-specific cardiac troponin T promoter ( Figure 3B ). Immunochemistry confirmed the labeling of cardiomyocyte in Rosa-mT-mG/cTNT-Cre embryos ( Figure 3C ). Hearts were dissected out from embryonic day 10.5 Rosa-mT-mG/ cTNT-Cre embryos and digested. EGFP-positive cardiomyocytes and EGFP-negative noncardiomyocytes were separated by fluorescence-activated cell sorting ( Figure 3D ). Quantitative reverse-transcriptase polymerase chain reaction detected high expression level of Myh6 (␣-myosin heavy chain) and CIP in the EGFP-positive cell sample but not in EGFPnegative cell sample, whereas endothelial markers Flk1, platelet/endothelial cell adhesion molecule 1, and fibrotic tissue marker Postn were highly expressed in EGFP-negative cell sample but not in the EGFP-positive cell sample ( Figure  3E , F, G; nϭ3). These data, together with the results of in situ hybridization, suggested that CIP is expressed in cardiomyocytes of developing hearts.
Next, we used a Cip gene trap mouse line in which a LacZ reporter gene was inserted into the Cip genomic locus (see Methods for details) to further map the expression of Cip in the heart (Online Figure III) . LacZ reporter gene expression was restricted to the developing heart at embryonic day 10.5 and embryonic day 13.5, recapitulating endogenous expression pattern of Cip and highlighting the cardiac specific expression of this gene ( Figure 4A , K). Immunohistochemistry analyses clearly demonstrated that the expression of Cip, as marked by ␤-galactosidase, overlapped with that of Nkx2-5, cardiac troponin T (TNNT2), and cardiac actin (ACTN2) in cardiomyocytes ( Figure 4B , C, D, G, J, yellow arrow heads). Cip-expressing cells did not coexpress WT1, a marker of epicardium, or platelet/endothelial cell adhesion molecule, a marker of endothelial cells ( Figure 4E , F, H, I, white arrows and arrow heads; nϾ3). Together these studies clearly demonstrate that Cip is specifically expressed in cardiomyocytes during embryogenesis. Interestingly, we detected CIP expression in the skeletal muscle of neonatal mice (Online Figure IV, middle). However, the expression of CIP in skeletal muscle appears to be transient, because we did not detect its expression in embryonic skeletal muscle (Online Figure 
CIP Interacts With Cardiac Transcriptional Factor Islet1
To identify putative CIP-interacting proteins, we performed yeast two-hybrid screening. The bait consisted of full-length CIP protein fused with the yeast GAL4 DNA binding domain. The bait construct did not autonomously activate transcription in yeast. We screened a mouse embryonic day 10.5 embryonic cDNA prey library and identified more than 30 positive clones, one of which encoded Islet1 (Isl1), a LIM/ homeodomain transcription factor essential for differentiation of second heart field cardiac progenitors. 23, 45 To confirm the interaction of CIP and Isl1, we performed coimmunoprecipitation assays. HEK293T cells were transfected with expression plasmids for FLAG-CIP, Myc-Isl1, or both. FLAG immunoprecipitates of cells expressing both constructs contained Isl1 protein, as demonstrated by Western blotting with anti-Myc antibodies. As negative controls, Isl1 was not detected in FLAG immunoprecipitates of cells transfected with each construct alone ( Figure 5A ). To further confirm direct interaction between CIP and Isl1, we per- formed in vitro GST-fusion protein pull-down assays. Isl1 was 35 S-labeled in a cell-free translation system, and the labeled Isl1 protein was then incubated with either GST-CIP fusion protein or GST protein alone (to serve as a negative control). As expected, GST-CIP fusion protein, but not GST alone, bound Isl1 ( Figure 5B ).
Next, we attempted to map the domains of these two proteins that mediate their interaction. We made series of deletion mutants and tested their interaction using coimmunoprecipitation assays. As shown in Figure 5C , the interaction between CIP and Isl1 is readily detected in full-length (1-309) and both C-terminal and N-terminal truncated mutants (1-200 and 100 -309). However, further C-terminal deletion (1-100) abolished the interaction, suggesting that regions between aa 100 and 200 are required for CIP to interact with Isl1 ( Figure 5C ). Similarly, we examined domains in the Isl1 protein that are needed for the interaction with CIP. We found that aa 1 to 133 fragment is sufficient to mediate the interaction, whereas the aa 79 to 349 region failed to interact ( Figure 5D ). These data indicate that the N-terminal region of the Isl1 protein is essential for its interaction with the CIP protein.
Isl1 is expressed in the cardiac progenitors and marks the second heart field. It was previously reported that Isl1 is not expressed in the cardiomyocytes of adult hearts. 23 We inves-tigated whether CIP and Isl1 are coexpressed in mouse embryos. The expression of Isl1 was examined in Cip-lacZ reporter embryos. As shown in Figures 5E and 5F , both LacZ and Isl1 were expressed in cardiomyocytes located in the outflow tract of embryonic day 10.5 mouse embryos ( Figure  5E , F, white arrowheads). However, Isl1 is not expressed in the cardiomyocytes of atrium or in the left ventricle, where CIP is expressed ( Figure 5F , yellow arrows). Given that Isl1 is expressed in cardiac progenitor cells of the second heart field and newly formed cardiomyocytes in the outflow tracts, 23 these results confirmed that CIP and Isl1 are coexpressed in the cardiac progenitor cells of embryonic hearts.
CIP Is a Transcription Cofactor of Isl1 and Regulates Its Transcriptional Activity
Because CIP was localized to the nucleus, we asked whether it possessed transcriptional activity. We fused the full-length CIP protein to the DNA-binding domain of yeast GAL4 protein. Interestingly, this fusion protein repressed the GAL4dependent reporter when cotransfected into HEK293T cells ( Figure 5G ). Similar, we observed that GAL4-CIP repressed the reporter in Hela and COS7 cells (data not shown).
Loss-of-function studies indicate that Isl1 is essential for cardiac development. 23 Isl1 activates the expression of the Mef2c gene by directly binding to its anterior heart field enhancer. 46 We tested whether CIP participates in regulation of the Mef2c anterior heart field enhancer. As expected, Isl1 constantly activated the Mef2c enhancer luciferase reporter, although its activity does not appear to be potent ( Figure 5I ). CIP alone did not significantly affect Mef2c enhancer activity. However, coexpression of Isl1 (the full-length, 1-309) and CIP inhibited Isl1-mediated Mef2c enhancer luciferase activity ( Figure 5I ). Further analyses, using different CIP deletion mutants, showed that the aa 1 to 200 and the aa 100 to 309 constructs (but not the aa 1-100) were able to repress Isl1-mediated activation of the Mef2c enhancer. These observations indicate that direct interaction of CIP and Isl1 is necessary for CIP to repress Isl1. Our results suggest that CIP is a transcription cofactor and represses the transcriptional activity of Isl1.
Next, we tested whether CIP represses the activity of other transcriptional regulators. Myocardin is a transcription factor specifically expressed in cardiac and smooth muscle that potently stimulates atrial natriuretic factor promoter activity in conjunction with the transcription factor serum response factor. 36 We found that CIP significantly repressed myocardin-mediated activation of the atrial natriuretic factorluciferase reporter ( Figure 5J) . Similarly, CIP also repressed serum response factor-dependent activation of the atrial natriuretic factor-luciferase reporter ( Figure 5J ). Together, our results indicated that CIP is a putative transcriptional repressor expressed in the heart.
The Expression of CIP Is Dysregulated in Hypertrophic Hearts
The heart undergoes cardiac remodeling in response to cardiac injury or stress. Increased pressure or volume overload in the heart results in cardiac hypertrophy, a process in which the size of cardiomyocytes increases without an increase in the number of cardiomyocytes. Interestingly, MEF2C was previously shown to be a key regulator of cardiac hypertrophy and dilated cardiomyopathy. 11, [47] [48] [49] [50] Because CIP repressed the Mef2c enhancer activity, we hypothesized that CIP regulates cardiac hypertrophy. We first examined whether hypertrophic signals regulate cardiac CIP expression. We used a transverse aortic constriction to induce pressure overload and subsequent pathological cardiac hypertrophy. As expected, atrial natriuretic peptide and B-type natriuretic peptide, well-known hypertrophy markers, were dramatically upregulated in transverse aortic constriction mice at day 3 and day 7 ( Figure 6A ). In contrast, Cip transcripts were substantially reduced in transverse aortic constriction mice. Similarly, expression of CIP was reduced in a second well-characterized cardiac hypertrophy model, 27 in which transgenic expression of activated calcineurin stimulates dramatic cardiac hypertrophy ( Figure 6B ).
In vivo cardiac hypertrophy models are complex and encompass both direct effects of inducing stimuli and secondary effects of myocardial responses, including cardiac fibrosis and failure. To directly examine the effect of hypertrophic stimuli on cardiomyocyte Cip expression, we used the well-established neonatal rat cardiomyocyte hypertrophy model. We treated neonatal rat cardiomyocytes with a panel of hypertrophic agonists and measured the effect on Cip expression. We found that the CIP protein level was significantly reduced in neonatal rat cardiomyocytes treated with the hypertrophic agonists leukemia inhibitory factor, endothelin-1, and phenylephrin (PE) ( Figure 6C ). Quantitative reverse-transcriptase polymerase chain reaction analyses of PE-treated cardiomyocytes corroborated this finding and indicated that CIP expression is regulated at the transcriptional level ( Figure 6D ). These results demonstrate that the expression of CIP is repressed in hypertrophic cardiomyocytes and hearts, in vitro and in vivo.
CIP Represses Cardiomyocyte Hypertrophy
These observations established an inverse correlation between the expression of CIP and cardiac hypertrophy and suggests that CIP could directly regulate cardiomyocyte hypertrophy. To test this hypothesis, we overexpressed CIP in cardiomyocytes by adenoviral gene transfer. Neonatal rat cardiomyocytes were isolated, cultured in vitro, and treated with PE to induce hypertrophy as previously described. 51 PE treatment dramatically induced cardiomyocyte hypertrophy, as measured by increased cell surface area ( Figure 6E ). Overexpression of CIP did not result in significant change to cardiomyocytes. However, CIP significantly attenuated PEinduced hypertrophy ( Figure 6E ). Quantification of cardiomyocyte size confirmed the observation (Figure 6F ). At the level of gene expression, PE induced expression of hypertrophic marker genes atrial natriuretic peptide, B-type natriuretic peptide, and ␤-myosin heavy chain, as expected. PE-induced expression of hypertrophic marker genes was inhibited by CIP ( Figure 6G ). Together, our results suggest that CIP negatively regulates cardiomyocyte hypertrophy.
Discussion
In the present study, we identified CIP as a novel cardiacspecific expressed nuclear protein. We demonstrated that CIP expression is restricted to cardiomyocytes. We further characterized CIP as a transcription cofactor of LIM/homeodomain transcription factor Isl1. We found that CIP physically interacts with Isl1 and represses its transcriptional activity. Functionally, we established that CIP represses cardiomyocyte hypertrophy.
We identified Isl1 as a CIP-interacting protein via unbiased yeast two-hybrid screening and subsequently confirmed their physical and functional interactions. Our data suggest that a direct interaction between these two proteins is needed for CIP to repress the transactivity of Isl1. Isl1 is expressed in the second heart field and is required for the morphogenesis of embryonic heart. 23 Interestingly, Isl1-positive progenitor cells were shown to be multi-potent and give rise to cardiac, smooth muscle, and endothelial cell lineages. 22, 52 Given that CIP interacts with Isl1 and is expressed in cardiac progenitors, we speculate that CIP might participate in the function of Isl1 in cell fate determination during early cardiac development. Despite its pivotal role in development, less is known , red) , DAPI (blue), and merged images were shown. Isl1 and CIP-positive cells were indicated by white arrowheads. Note that Isl1 is not expressed in the cardiomyocytes of atrium where CIP is expressed (yellow arrows). G, CIP is a transcriptional repressor. HEK293T cells were transiently transfected with expression vectors encoding the CIP fused to GAL4 (1-147) and the pL8G5-luciferase reporter, which contains binding sites for the GAL4 DNA binding domain. Luciferase activity is expressed as relative activity in which the control was assigned a value of 1. Data represent the meanϮSD from at least three independent experiments in triplicate. *PϽ0.05. H, CIP represses the transcription activity of Isl1. MEF2C enhancerluciferase reporter was cotransfected with indicated expression plasmids in HEK293T cells and luciferase activity was measured. Results were presented as relative luciferase activity in which the control was assigned a value of 1. Data represent the meanϮSD from at least three independent experiments in triplicate. *PϽ0.05. I, Define the domains of the CIP protein that mediate the repression of Isl1 transcription activity. MEF2C enhancer-luciferase reporter was cotransfected with indicated expression plasmids (full-length Isl1, full-length or truncated CIP mutants) in HEK293T cells and luciferase activity was measured. Results were presented as relative luciferase activity in which the control was assigned a value of 1. Data represent the meanϮSD from at least three independent experiments in triplicate. *PϽ0.05. J, CIP represses myocardin-mediated and serum response factor-mediated transactivation of the atrial natriuretic factor (ANF)-luciferase reporter. The ANF-luciferase reporter was cotransfected with indicated expression plasmids in HEK293T cells and luciferase activity was measured. Results were presented as relative luciferase activity in which the control was assigned a value of 1. Data represent the meanϮSD from at least three independent experiments in triplicate. *PϽ0.05. about how Isl1 works at the molecular level. Isl1 is a LIM/homeodomain transcription factor and it synergistically activates insulin gene transcription with BETA2 in pancreatic beta cells. 53 Furthermore, Isl1 forms a complex with Jak1 and Stat3 and triggers the tyrosine phosphorylation of Jak1 and its kinase activity. 54 Isl1 works upstream of the sonic hedgehog signaling and the MEF2C transcription factor in the heart. 21, 46 Our data showed that the transcriptional activity of Isl1, although not very strong when compared with many other transcription factors, was repressed by CIP. This suggests another layer of regulation of this transcription factor.
In addition to its unique cardiac expression pattern, several lines of evidences point to CIP as an important regulator of cardiac gene expression and cardiac hypertrophy. Intriguingly, our data showed the capability of CIP to repress Isl1-mediated activation of the MEF2C enhancer. It had been shown that MEF2C was upregulated during pathological hypertrophy. 50 Transgenic mice expressing a dominantnegative MEF2C displayed attenuated postnatal growth of myocardium. 48, 49 Given the critical role of MEF2C in cardiac development and hypertrophy, it is reasonable to predict that CIP is also involved in this process. Consistent with this view, we found that the expression level of CIP was consistently downregulated in cardiac hypertrophy models, both in vivo and in vitro. Most importantly, we provide evidence to demonstrate that overexpression of CIP partially represses agonist-induced cardiomyocyte hypertrophy. It remains to be determined, using genetic approaches, whether CIP participates in the regulation of cardiac gene expression during heart development and whether dysregulation of CIP expression will lead to cardiac pathophysiological condition or human cardiovascular disease. It will also be important to understand how CIP participates in the regulatory pathways of cardiac hypertrophy.
CIP is evolutionarily conserved in vertebrate. Its orthologs were found in things from fish to humans, suggesting it has conserved biological function and may play an important role in cardiac development and disease. CIP appears to stand as a single member of this class of protein, and no homologous protein is encoded in the mouse genome. Recently, another splice variant in the locus of 2310046A06Rik was identified as a lamin-interacting protein (MLIP). 44 MLIP was shown to interact directly with lamin A/C (LMNA), a nuclear envelope protein. Interestingly, LMNA is known to interact with many transcription factors/cofactors, including retinoblastoma transcriptional regulator (RB), 55 germ cell-less, 56 sterol response element binding protein, 57 C-Fos, 58 and zinc finger protein 239. 59 However, the functional significance of such interaction remains to be fully understood. LMNA is essential for the function of heart and human patients with LMNA mutation often exhibit adult-onset dilated cardiomyopathy accompanied with conduction-system disease. 60 LMNA-null mice display severe skeletal muscle atrophy and dilated cardiomyopathy and die by 8 weeks. 61, 62 These observations suggest that the LMNA-interacting protein CIP/MLIP could be part of the network that regulates gene expression in LMNA-related dilated cardiomyopathy. It will be interesting to understand how CIP/MLIP modulates the function of LMNA and, most importantly, whether CIP/MLIP is directly related to human cardiac and muscle diseases.
Our data demonstrate that CIP is expressed in the developing and adult heart. More specifically, we show that CIP expression is restricted to cardiomyocytes and cardiac progenitors during development. We have also observed transient CIP expression in the skeletal muscle. However, the level of CIP expression in skeletal muscle appears to be low when compared with that of cardiac muscle. Moreover, skeletal muscle expression of CIP is not detected at all stages of embryos or postnatal mice. It will be interesting to investigate whether CIP plays a role in skeletal muscle development and function.
Database Searching and Cloning of CIP
We screened for novel cardiac-specific genes in silico by performing a Basic Local Alignment Search Tool search with expressed sequence tags from mouse embryonic heart cDNA libraries in the database as described previously. 36 One of the cDNA sequences identified in this screen (access number AA919489) corresponded to the 3Ј untranslated region of the CIP transcript and was found in a cDNA library of embryonic day 13.5 mouse embryonic hearts. This short cDNA fragment (273 nt) was used as a probe to screen a mouse embryonic heart cDNA library. Several cDNA clones were identified. Among them, the longest clone is 1336 nt in length. Polymerase chain reaction-based cloning was further used to identify additional cDNA isoforms.
CIP Reporter Mice
The CIP reporter line with a retroviral gene trap cassette inserted into mouse genome chromosome 9 (between chromosome 9: 77 046 001 and 77 046 002) was generated and obtained from Texas A&M Institute for Genomic Medicine. The gene trap cassette containing the selectable marker ␤-geo, a functional fusion between the ␤-galactosidase and neomycin resistance gene, was inserted into the putative third intron of the CIP gene (Online Figure III) .
In Situ Hybridization and Northern Analysis
Whole-mount and section in situ hybridization and Northern analyses were performed as described. 36, 63 The 273 nt cDNA fragment corresponding to the 3Ј untranslated region of the CIP gene was used as a probe to perform both whole-mount and tissue section in in situ hybridization on staged mouse embryos.
Constructs, Cell Culture, and Luciferase Reporter Assays
Hela, COS7, and HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine serum in a 5% CO 2 atmosphere at 37°C. Luciferase reporter constructs fused with the MEF2C enhancer were as reported and are generous gifts of Dr. Brian Black (University of California, San Francisco). 46 Transfections were performed with either FuGENE6 (Roche) or lipofectamine (Invitrogen) reagents according to manufacturer instructions. Unless otherwise indicated, 100 ng of reporter plasmid and 100 ng of each activator plasmid were applied; 48 hours after transfection, cell extracts were pre-pared and luciferase activity was determined. For luciferase assay, normalized luciferase expression from triplicate samples in 12-well plates relative to LacZ expression was calculated, and the results are expressed as fold activation over the value relative to the control (luciferase reporter and empty pcDNA). The CIP adenoviral expression construct contained full-length CIP cDNA and was constructed as previously described. 51
Tissue Dissociation and Cell Sorting of Mouse Embryos
The embryonic day 10.5 embryonic hearts were isolated by microdissection and dissociated to single cells by collagenase digestion as previously described. 64 Isolated cells were fluorescence-activated cell-sorted into green fluorescent proteinpositive and green fluorescent protein-negative populations. Sorted cells were collected into Trizol (Invitrogen) and frozen at Ϫ20°C for RNA isolation.
Immunochemistry and ␤-Galactosidase Staining
Staged mouse embryos were dissected out, collected, and fixed in 4% paraformaldehyde at 4°C for 4 hours. After washing in phosphate-buffered saline, embryos were treated in 15% and 30% sucrose for 2 hours each and embedded in OCT. Approximately 5-m to 8-m cryostat sections were collected on positively charged slides. Sections were washed in phosphate-buffered saline, blocked in 5% serum/ phosphate-buffered saline, and subjected to immunostaining. Antibody sources were as follows: green fluorescent protein (Invitrogen); platelet/endothelial cell adhesion molecule (BD Biosciences); Nkx2-5 (Santa Cruz); Wt1 (Santa Cruz); cardiac Troponin T (Tnnt2; generous gift of Dr. Jim Lin, University of Iowa); cardiac Troponin I (Tnni3; Santa Cruz); Actn2 (Sigma); Isl1 (DSHB; University of Iowa); and ␤-galatosidase (MP Biomedical). Alexa-488 and Alexa-594 secondary antibodies (Invitrogen). Fluorescently stained slides were counterstained with DAPI and imaged with an FV1000 confocal microscope (Olympus). For ␤-galactosidase staining, samples were stained with a solution containing 5 mmol/L potassium ferricyanide, 5 mmol/L potassium ferrocyanide, and 1 mg/mL X-gal substrate at 37°C for 12 hours after fixation.
Quantitative Reverse-Transcriptase Polymerase Chain Reaction and Western Blot Analyses
Total RNAs were isolated using Trizol reagent (Invitrogen) from cells and tissue samples. For quantitative reversetranscriptase polymerase chain reaction, 2.0-g RNA samples were reverse-transcribed to cDNA by using random hexamers and moloney murine leukemia virus reversetranscriptase (Invitrogen) in a 20-L reaction system. In each analysis, 0.1 L cDNA pool was used for quantitative polymerase chain reaction. For Western blot analyses, cell extractions were cleared by 10 000g centrifugation for 10 minutes at 4°C. Samples were subsequently separated by SDS/PAGE and transferred to polyvinylidene fluoride membranes that were incubated with 5% milk and anti-FLAG (1:1000; Sigma), anti-Myc (1:1000; Santa Cruz), and ␤-tubulin (1:10 000; Sigma) overnight at 4°C and then washed three times with tris-buffered saline tween-20 buffer before adding secondary antibody. Polyclonal antibodies against the CIP protein were generated by immunizing rabbits with CIP proteins that were expressed and purified as GST-CIP fusion proteins in bacterial. Specific protein bands were visualized by using enhanced chemiluminescence (Invitrogen) reagents.
Coimmunoprecipitation Assays
COS7 cells were transiently transfected with plasmids encoding FLAG-tagged CIP and Myc-tagged Isl1 proteins with FuGENE6 (Roche). Cells were harvested 48 hours after transfection in lysis buffer composed of 1ϫ phosphatebuffered saline containing 0.5% Triton X-100, 1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 150 mmol/L of NaCl, and complete protease inhibitors (Roche). After a brief sonication and removal of cellular debris by centrifugation, FLAG-tagged CIP proteins were precipitated with anti-FLAG antibodies and protein A/G beads and associated proteins were analyzed by Western blotting with anti-Myc antibodies.
In Vitro GST Protein-Binding Assays
Plasmids encoding a GST fusion with CIP were transformed into BL21 plus cells (Stratagene). The cells were grown at 37°C in 2ϫ yeast-extract tryptone medium to an optical density of 1.0. Isopropyl-␤-D-thiogalactopyranoside (50 mol/L) was then added to the culture to induce protein expression. After being shaken at room temperature for 4 hours, the cells were harvested and the GST protein was purified with glutathione beads. Isl1 proteins translated in vitro were labeled with 35S methionine by using a TNT T7 reticulocyte lysate system (Promega). Glutathione beads conjugated with GST fusion protein were incubated with 10 L of TNT product at 4°C for 2 hours in 500 L of GST-binding buffer (20 mmol/L Tris, pH 7.3/150 mmol/L NaCl/0.5% Nonidet P-40/protease inhibitor/1 mmol/L phenylmethylsulfonyl fluoride). The beads were washed three times with GST-binding buffer; 50 L of SDS loading buffer was then added to the beads. After boiling, 20 L was loaded onto an SDS/PAGE gel and analyzed by autoradiography.
Cardiomyocyte Culture
Neonatal rat cardiomyocytes were prepared as previously described. 51 Briefly, 18 hours after plating, cells were changed into serum-free medium and infected with adenovirus (Ad-GFP for control and Ad-CIP) at a multiplicity of infection of 25. Twenty-four hours later, cells were treated with hypertrophic agents PE. Cells were harvested 24 hours after PE treatment for RNA isolation or 48 hours after PE treatment for immunochemistry.
